ArticleNeuroImage. Clinical2026
Three-Dimensional quantitative analysis of the Peri-Enhancing zone reveals ADC and CBV signatures of glioblastoma recurrence.
Article in NeuroImage. Clinical, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAccurate detection of glioblastoma infiltration and early peri-enhancing changes that predict recurrence remains challenging. We present a three-dimensional (3D) quantitative framework to characterize the peri-enhancing zone (PEZ) on baseline and follow-up MRI and examine whether baseline ADC and CBV differentiate regions that subsequently recur from those that remain stable.
methodsWe retrospectively analyzed patients with IDH wild-type glioblastoma who developed local recurrence within 12 months post-resection. The contrast-enhancing tumor core including the necrotic region, and surrounding FLAIR hyperintensity were segmented in 3D on diagnostic MRI. Local recurrence was identified on follow-up MRI as abnormal T1 enhancement contiguous with the initial T1-enhancing core and mapped onto baseline images. The PEZ (up to 5 voxels surrounding the T1-enhancing core) was divided by FLAIR signal into hyperintense (PEZ
resultsOf 101 eligible patients, 59 developed local recurrence and 46 were included in the final analysis. The mean PEZ
conclusions3D volumetric analysis of the PEZ reveals distinct ADC and CBV signatures in regions predisposed to recurrence, which are not apparent on conventional MRI. Differences were confined to FLAIR-hyperintense regions, highlighting the need for novel imaging strategies to detect at-risk tissue in FLAIR-normal PEZ. Importantly, we present a new 3D evaluation approach linking baseline and follow-up MRI that can be applied to investigate other clinical and research questions in brain tumor imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.